Company profile
INNATE PHARMA SA
NASDAQ:IPHABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IPH-2101 | phase2 | — | 3 | no active trials |
| LACUTAMAB | phase2 | — | 3 | no active trials |
| MONALIZUMAB | phase1_2 | — | 3 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01256073 | phase1 | completed | 2007-02-01 | 2013-07-01 | Innate Pharma | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia |
| NCT00552396 | phase1 | completed | 2007-05-01 | 2011-01-01 | Innate Pharma | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma |
| NCT02557516 | phase1_2 | terminated | 2015-11-09 | 2018-10-29 | Innate Pharma | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL |
| NCT01687387 | phase2 | completed | 2012-10-01 | 2016-11-17 | Innate Pharma | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) |
| NCT02331875 | phase1_2 | terminated | 2014-12-01 | 2016-12-01 | Innate Pharma | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity |
FDA applications (0)
No records yet.